Compass Therapeutics Inc. (NASDAQ: CMPX) announced that its experimental drug tovecimig met a key secondary endpoint in a Phase 2/3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

H.C. Wainwright on Compass Therapeutics (CMPX): 'we do believe the probability of a path forward is meaningfully higher than the market reaction observed'April 27, 2026 11:50 AM Leerink on Compass Therapeutics (CMPX): 'there are multiple sources of long-term upside'April 27, 2026 10:20 AM Stifel on Compass Therapeutics (CMPX): 'Path Forward Complicated by FDA’s “Imply-No-Harm” Mandate'April 27, 2026 8:27 AM William Blair on Compass Therapeutics (CMPX) 75% Drop: 'This will raise questions on the approvability of this dataset'April 27, 2026 8:08 AM